Gene: FAM19A4

151647
TAFA-4|TAFA4
family with sequence similarity 19 member A4, C-C motif chemokine like
protein-coding
3p14.1
Ensembl:ENSG00000163377 MIM:617498 Vega:OTTHUMG00000158744 UniprotKB:Q96LR4
NC_000003.12
SNP Mapped
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
5.359e-1 (AD)  3.626e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs6770678chr3:68911859 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ANO40.736
GNAI10.735
RAB33A0.723
ALCAM0.718
HBS1L0.699
CRHBP0.693
LDLRAD40.691
ENPP60.683
STK390.682
RAP1GDS10.68

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
INHBB-0.462
STON2-0.435
NHSL1-0.432
ALAS2-0.431
RHOJ-0.429
FCN1-0.428
SLC4A1-0.426
RREB1-0.424
HIF3A-0.423
CA1-0.421

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A4 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A4 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of FAM19A4 mRNA21641981
D000517alpha-Chlorohydrinalpha-Chlorohydrin results in decreased expression of FAM19A4 mRNA28522335
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of FAM19A4 mRNA20106945|2163298
C006780bisphenol Abisphenol A results in decreased expression of FAM19A4 mRNA25181051
D016572CyclosporineCyclosporine results in decreased expression of FAM19A4 mRNA25562108
C118739entinostatentinostat results in increased expression of FAM19A4 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A4 mRNA"27188386
D004397FonofosFonofos results in increased methylation of FAM19A4 promoter22847954
D010278ParathionParathion results in increased methylation of FAM19A4 promoter22847954
D011441PropylthiouracilPropylthiouracil results in increased expression of FAM19A4 mRNA24780913
D011794QuercetinQuercetin results in decreased expression of FAM19A4 mRNA21632981
C012568terbufosterbufos results in increased methylation of FAM19A4 promoter22847954
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of FAM19A4 mRNA20106945|2163298
C012589trichostatin Atrichostatin A results in increased expression of FAM19A4 mRNA24935251
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM19A4 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of FAM19A4 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of FAM19A4 mRNA23179753|2438349

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI25416956  
GO ID GO Term Qualifier Evidence PubMed
GO:0042391regulation of membrane potential-IEA-  
GO:0051930regulation of sensory perception of pain-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal